Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsKay-Gunnar STUBENRAUCH, Ekkehard MOESSNER, Christian KLEIN, Diana DAROWSKI
Estimating the term…
The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain. The invention also provides the production and use of T cells in a method for the treatment of particular diseases in conjunction with tumor-specific antibodies as well as pharmaceutical compositions/medicaments comprising T cells and/or therapeutic antibodies, wherein T cells are to be administered in combination with therapeutic-tumor targeting antibody/antibodies comprising a mutated Fc domain with reduced Fc receptor binding.
1-30. (canceled)
A transduced T cell capable of expressing an antigen binding receptor comprising an anchoring transmembrane domain and an extracellular domain comprising an antigen binding moiety, wherein the antigen binding moiety is capable of specific binding to a mutated fragment crystallizable (Fc) domain but not capable of specific binding to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises at least one amino acid substitution compared to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises the amino acid mutation P329G according to EU numbering, wherein the antigen binding moiety is capable of specific binding to the mutated Fc domain comprising the P329G mutation but not capable of specific binding to the non-mutated parent Fc domain, and wherein the antigen binding moiety comprises:
A transduced T cell capable of expressing an antigen binding receptor comprising an anchoring transmembrane domain and an extracellular domain comprising an antigen binding moiety, wherein the antigen binding moiety is capable of specific binding to a mutated Fc domain but not capable of specific binding to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises at least one amino acid substitution compared to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises the amino acid mutations I253A, H310A, and H435A according to EU numbering, wherein the antigen binding moiety is capable of specific binding to the mutated Fc domain comprising the I253A, H310A, and H435A mutations but not capable of specific binding to the non-mutated parent Fc domain, and wherein the antigen binding moiety comprises:
An isolated polynucleotide encoding an antigen binding receptor comprising an anchoring transmembrane domain and an extracellular domain comprising an antigen binding moiety, wherein the antigen binding moiety is capable of specific binding to a mutated fragment crystallizable (Fc) domain but not capable of specific binding to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises at least one amino acid substitution compared to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises the amino acid mutation P329G according to EU numbering, wherein the antigen binding moiety is capable of specific binding to the mutated Fc domain comprising the P329G mutation but not capable of specific binding to the non-mutated parent Fc domain, and wherein the antigen binding moiety comprises:
An isolated polynucleotide encoding an antigen binding receptor comprising an anchoring transmembrane domain and an extracellular domain comprising an antigen binding moiety, wherein the antigen binding moiety is capable of specific binding to a mutated Fc domain but not capable of specific binding to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises at least one amino acid substitution compared to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises the amino acid mutations I253A, H310A, and H435A according to EU numbering, wherein the antigen binding moiety is capable of specific binding to the mutated Fc domain comprising the I253A, H310A, and H435A mutations but not capable of specific binding to the non-mutated parent Fc domain, and wherein the antigen binding moiety comprises:
Dependencies are inferred from the claim text.